Loading
A phase 1/2 trial of Patritumab deruxtecan, Trastuzumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) is a phase 1/2 interventional study registered as NCT06686394 by Merck Sharp & Dohme LLC, with 81 participants planned, started 2025-02-26 and due to reach its primary completion in 2030-04-18. Interventions recorded: Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar, Pertuzumab and Tucatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Tucatinib, Pertuzumab, Daiichi Sankyo, HER2-positive breast cancer and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/